Capital investment and personnel development with a view to establishing a clinical laboratory testing business
First written in FY2017. 4 of 6 entries say "Advanced", first in FY2021. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「Cost reductions and improved productivity associated with the closure of Akita Analysis Center (Akita Prefecture) and consolidation into IBL Analysis Center (Gunma Prefecture)」
The testing structure was reorganized by closing Akita Analysis Center and consolidating operations at IBL Analysis Center in Gunma Prefecture. The resulting cost reductions and productivity gains were cited as factors improving profit in the antibody-related business. - FY2023AdvancedAnnual report
「In addition to its partnership with a major testing company, the company began offering contract testing services using “PXB-cells LA,” a material for lipid metabolism research, through a business partnership with PhoenixBio Co.,Ltd. It will continue to provide contract testing services on a stable basis while expanding them.」
In the clinical and research testing business, the company began offering contract testing services using PXB-cells LA through its partnership with PhoenixBio Co.,Ltd., in addition to its partnership with a major testing company. - FY2023-Q2AdvancedAnnual report
「Revenue from contract testing services using the company's own ELISA kits at the clinical testing center increased.」
Revenue from contract testing services using the company's own ELISA kits at the clinical testing center increased. Operations for contract testing through the existing testing infrastructure have continued and progressed. - FY2021AdvancedAnnual report
「At IBL Analysis Center, a registered sanitary testing laboratory established at IBL's Fujioka Research Institute, the company conducts research testing using IBL's proprietary ELISA measurement kits and contract testing of HPLC measurement items based on LipoSEARCH, in partnership with a major testing company. It will continue to pursue an increase in the number of tests.」
The plan for a clinical testing business took concrete shape through the opening of IBL Analysis Center and the provision of contract testing in partnership with a major testing company. - FY2019RestatedAnnual report
「The business will also make capital investments and develop personnel with a view to establishing a clinical testing business, for the purpose of promoting research and development in the diagnostics and reagents business and expanding demand for products under development.」
The company has reaffirmed its policy of making capital investments and developing personnel with a view to establishing a clinical testing business, aiming to create synergies with the diagnostics and reagents business. - FY2017First statedAnnual report
「The business will also make capital investments and develop personnel with a view to establishing a clinical testing business, for the purpose of promoting research and development in the diagnostics and reagents business and expanding demand for products under development.」
For the testing business, the company has for the first time stated a policy of making capital investments and developing personnel with a view to establishing a clinical testing business, aiming to create synergies with the diagnostics and reagents business.